Neoadjuvant radiotherapy improves overall survival for T3/4N+M0 rectal cancer patients: a population-based study of 20300 patients
Tóm tắt
Neoadjuvant radiotherapy (RT) has been shown to improve local control; however, whether it can improve overall survival (OS) in locally advanced rectal cancer (LARC) patients remains controversial. We therefore aimed to examine the benefits of surgery alone, neoadjuvant radiotherapy (RT), adjuvant RT, and surgery plus chemotherapy in stage II (T3/4N0M0) and III (any T and N + M0) on the OS of rectal cancer patients. Date from the Surveillance, Epidemiology, and End Results (SEER) database diagnosed between 2004 and 2016 were used. Kaplan-Meier analyses were used to compare patient prognoses across different treatment modalities. Cox hazard regression analysis were used to identify independent predictors of OS. For stage T3/4N0M0 patients, neoadjuvant RT, adjuvant RT, and surgery plus chemotherapy resulted in similar OS (all p > 0.05; mean survival, 115.89 months (M), 111.97 M, and 117.22 M, respectively), with better OS observed in these patients than in patients who underwent surgery alone (all p < 0.001, mean survival, 88.96 M). For stage T1/2N + M0 patients, neoadjuvant RT, adjuvant RT, and surgery plus chemotherapy resulted in similar OS (all p > 0.05; mean survival, 121.50 M, 124.25 M, and 121.20 M, respectively), with better OS observed in these patients than in patients who underwent surgery alone (all p < 0.001, mean survival 83.81 M). For stage T3/4N + M0 patients, neoadjuvant RT (HR = 0.436; 95% CI, 0.396~0.478; p < 0.001) resulted in significantly longer OS than adjuvant RT and surgery plus chemotherapy (mean survival, 104.47 M, 93.94 M, and 93.62 M, respectively), with better OS observed in these patients than in patients who underwent surgery alone (all p < 0.001, mean survival 54.87 M). Older age (> 60 years), black race, unmarried status, high tumour grade, and tumour size > 5 cm were all associated with a poor prognosis (all p < 0.05). Neoadjuvant RT, adjuvant RT, and surgery plus chemotherapy results in better OS than surgery alone in LARC patients. Neoadjuvant RT has the potential to be highly recommended over adjuvant RT and surgery plus chemotherapy for T3/4N + M0 patients; however, it showed no OS advantage over adjuvant RT or surgery plus chemotherapy for T3/4N0M0 and T1/2N + M0 patients.
Tài liệu tham khảo
Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester R, Barzi A, Jemal A. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67(3):177–93. https://doi.org/10.3322/caac.21395.
Song JH, Jeong JU, Lee JH, Kim SH, Cho HM, Um JW, Jang HS. Preoperative chemoradiotherapy versus postoperative chemoradiotherapy for stage II–III resectable rectal cancer: a meta-analysis of randomized controlled trials. Radiat Oncol J. 2017;35(3):198–207. https://doi.org/10.3857/roj.2017.00059.
Li Y, Wang J, Ma X, Tan L, Yan Y, Xue C, Hui B, Liu R, Ma H, Ren J. A review of Neoadjuvant Chemoradiotherapy for locally advanced rectal Cancer. Int J Biol Sci. 2016;12(8):1022–31. https://doi.org/10.7150/ijbs.15438.
Cedermark B, Dahlberg M, Glimelius B, Pahlman L, Rutqvist LE, Wilking N. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med. 1997;336(14):980–7. https://doi.org/10.1056/NEJM199704033361402.
Medical Research Council Rectal Cancer Working Party. Randomised trial of surgery alone versus radiotherapy followed by surgery for potentially operable locally advanced rectal cancer. Lancet. 1996;348(9042):1605–10.
Cedermark B, Johansson H, Rutqvist LE, Wilking N. The Stockholm I trial of preoperative short term radiotherapy in operable rectal carcinoma. A prospective randomized trial. Stockholm colorectal Cancer study group. Cancer. 1995;75(9):2269–75. https://doi.org/10.1002/1097-0142(19950501)75:9<2269::aid-cncr2820750913>3.0.co;2-i.
Dahl O, Horn A, Morild I, Halvorsen JF, Odland G, Reinertsen S, Reisaeter A, Kavli H, Thunold J. Low-dose preoperative radiation postpones recurrences in operable rectal cancer. Results of a randomized multicenter trial in western Norway. Cancer. 1990;66(11):2286–94. https://doi.org/10.1002/1097-0142(19901201)66:11<2286::aid-cncr2820661106>3.0.co;2-t.
Fisher B, Wolmark N, Rockette H, Redmond C, Deutsch M, Wickerham DL, Fisher ER, Caplan R, Jones J, Lerner H, et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst. 1988;80(1):21–9. https://doi.org/10.1093/jnci/80.1.21.
Fichera A. Locally advanced rectal Cancer: is it time for a paradigm change? JAMA Surg. 2018;153(8):e181620. https://doi.org/10.1001/jamasurg.2018.1620.
Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet. 1986;1(8496):1479–82. https://doi.org/10.1016/s0140-6736(86)91510-2.
van Gijn W, Marijnen CA, Nagtegaal ID, Kranenbarg EM, Putter H, Wiggers T, Rutten HJ, Pahlman L, Glimelius B, van de Velde CJ. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12(6):575–82. https://doi.org/10.1016/S1470-2045(11)70097-3.
Rodel C, Graeven U, Fietkau R, Hohenberger W, Hothorn T, Arnold D, Hofheinz RD, Ghadimi M, Wolff HA, Lang-Welzenbach M, et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2015;16(8):979–89. https://doi.org/10.1016/S1470-2045(15)00159-X.
Schrag D, Weiser MR, Goodman KA, Gonen M, Hollywood E, Cercek A, Reidy-Lagunes DL, Gollub MJ, Shia J, Guillem JG, et al. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. J Clin Oncol. 2014;32(6):513–8. https://doi.org/10.1200/JCO.2013.51.7904.
Qin Q, Huang B, Cao W, Zhou J, Ma T, Zhou Z, Wang J, Wang L. Bowel dysfunction after low anterior resection with Neoadjuvant Chemoradiotherapy or chemotherapy alone for rectal Cancer: a cross-sectional study from China. Dis Colon Rectum. 2017;60(7):697–705. https://doi.org/10.1097/DCR.0000000000000801.
Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, Becker H, Raab H, Villanueva M, Witzigmann H, et al. Preoperative versus postoperative Chemoradiotherapy for locally advanced rectal Cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30(16):1926–33. https://doi.org/10.1200/JCO.2011.40.1836.
Peng LC, Milsom J, Garrett K, Nandakumar G, Coplowitz S, Parashar B, Nori D, Clifford Chao KS, Wernicke AG. Surveillance, epidemiology, and end results-based analysis of the impact of preoperative or postoperative radiotherapy on survival outcomes for T3N0 rectal cancer. Cancer Epidemiol. 2014;38(1):73–8. https://doi.org/10.1016/j.canep.2013.12.008.
Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, Rutten HJ, Pahlman L, Glimelius B, van Krieken JH, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345(9):638–46. https://doi.org/10.1056/NEJMoa010580.
Tan WJ, Tan HJ, Dorajoo SR, Foo FJ, Tang CL, Chew MH. Rectal Cancer surveillance-recurrence patterns and survival outcomes from a cohort followed up beyond 10 years. J Gastrointest Cancer. 2018;49(4):422–8. https://doi.org/10.1007/s12029-017-9984-z.
Zhao F, Wang J, Chen M, Chen D, Ye S, Li X, Chen X, Ren G, Yan S. Sites of synchronous distant metastases and prognosis in prostate cancer patients with bone metastases at initial diagnosis: a population-based study of 16,643 patients. Clin Transl Med. 2019;8(1). https://doi.org/10.1186/s40169-019-0247-4.
Qin B, Jiao X, Yuan L, Liu K, Zang Y. Adenosquamous carcinoma of the bile duct: a population-based study. Cancer Manag Res. 2018;10:439–46. https://doi.org/10.2147/CMAR.S144850.
Zhong X, Guo Z, Gao P, Song Y, Sun J, Chen X, Sun Y, Wang Z. Racial/ethnic disparities in the adjuvant chemotherapy of locally advanced colon cancer patients. J Surg Res. 2018;228:27–34. https://doi.org/10.1016/j.jss.2018.02.054.
Kornprat P, Pollheimer MJ, Lindtner RA, Schlemmer A, Rehak P, Langner C. Value of tumor size as a prognostic variable in colorectal Cancer: a critical reappraisal. Am J Clin Oncol. 2011;34(1):43–9. https://doi.org/10.1097/COC.0b013e3181cae8dd.
Diaz BR, Akhoundova D, Bruixola G, Aparicio J. Controversies in the multimodality management of locally advanced rectal cancer. Med Oncol. 2017;34(6):102. https://doi.org/10.1007/s12032-017-0964-8.
Park JH, Yoon SM, Yu CS, Kim JH, Kim TW, Kim JC. Randomized phase 3 trial comparing preoperative and postoperative chemoradiotherapy with capecitabine for locally advanced rectal cancer. Cancer. 2011;117(16):3703–12. https://doi.org/10.1002/cncr.25943.
Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731–40. https://doi.org/10.1056/NEJMoa040694.
Roh MS, Colangelo LH, O’Connell MJ, Yothers G, Deutsch M, Allegra CJ, Kahlenberg MS, Baez-Diaz L, Ursiny CS, Petrelli NJ, et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol. 2009;27(31):5124–30. https://doi.org/10.1200/JCO.2009.22.0467.
Rahbari NN, Elbers H, Askoxylakis V, Motschall E, Bork U, Büchler MW, Weitz J, Koch M. Neoadjuvant radiotherapy for rectal Cancer: meta-analysis of randomized controlled trials. Ann Surg Oncol. 2013;20(13):4169–82. https://doi.org/10.1245/s10434-013-3198-9.
McCarthy K, Pearson K, Fulton R, Hewitt J. Pre-operative chemoradiation for non-metastatic locally advanced rectal cancer. Cochrane Database Syst Rev. 2012;12:CD008368. https://doi.org/10.1002/14651858.CD008368.pub2.
Collette L, Bosset JF, den Dulk M, Nguyen F, Mineur L, Maingon P, Radosevic-Jelic L, Pierart M, Calais G. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer radiation oncology group. J Clin Oncol. 2007;25(28):4379–86. https://doi.org/10.1200/JCO.2007.11.9685.
Gerard JP, Conroy T, Bonnetain F, Bouche O, Chapet O, Closon-Dejardin MT, Untereiner M, Leduc B, Francois E, Maurel J, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006;24(28):4620–5. https://doi.org/10.1200/JCO.2006.06.7629.
Cercek A, Roxburgh C, Strombom P, Smith JJ, Temple L, Nash GM, Guillem JG, Paty PB, Yaeger R, Stadler ZK, et al. Adoption of Total Neoadjuvant therapy for locally advanced rectal Cancer. JAMA Oncol. 2018;4(6):e180071. https://doi.org/10.1001/jamaoncol.2018.0071.
Zaborowski A, Stakelum A, Winter DC. Systematic review of outcomes after total neoadjuvant therapy for locally advanced rectal cancer. Br J Surg. 2019;106(8):979–87. https://doi.org/10.1002/bjs.11171.
Bosse D, Mercer J, Raissouni S, Dennis K, Goodwin R, Jiang D, Powell E, Kumar A, Lee-Ying R, Price-Hiller J, et al. PROSPECT eligibility and clinical outcomes: results from the pan-Canadian rectal Cancer consortium. Clin Colorectal Cancer. 2016;15(3):243–9. https://doi.org/10.1016/j.clcc.2016.02.003.
Appelt AL, Bentzen SM, Jakobsen A, Vogelius IR. Dose-response of acute urinary toxicity of long-course preoperative chemoradiotherapy for rectal cancer. Acta Oncol. 2015;54(2):179–86. https://doi.org/10.3109/0284186X.2014.923933.
Peeters KC, van de Velde CJ, Leer JW, Martijn H, Junggeburt JM, Kranenbarg EK, Steup WH, Wiggers T, Rutten HJ, Marijnen CA. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients--a Dutch colorectal cancer group study. J Clin Oncol. 2005;23(25):6199–206. https://doi.org/10.1200/JCO.2005.14.779.
Warschkow R, Güller U, Cerny T, Schmied BM, Plasswilm L, Putora PM. Secondary malignancies after rectal cancer resection with and without radiation therapy: a propensity-adjusted, population-based SEER analysis. Radiother Oncol. 2017;123(1):139–46. https://doi.org/10.1016/j.radonc.2017.02.007.
Lai L, Fuller C, Kachnic L, Thomasjr C. Can pelvic radiotherapy be omitted in select patients with rectal Cancer? Semin Oncol. 2006;33(6 Suppl 11):S70–4. https://doi.org/10.1053/j.seminoncol.2006.10.019.
Eisterer W, Piringer G, DE Vries A, Ofner D, Greil R, Tschmelitsch J, Samonigg H, Solkner L, Gnant M, Thaler J. Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study. Anticancer Res. 2017;37(5):2683–91. https://doi.org/10.21873/anticanres.11617.